Drugs / AMG 513
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Clinical hold | US (FDA) | — | obesity disorder | 2025-02-04 | “A Phase 1 study of AMG 513 in people living with obesity was placed on clinical hold by the U.S. Food and Drug Administration (FDA).” amgen.com ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06585462 | Sep 2024 → Oct 2026 expected | metabolic disease | Amgen | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG 513 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06585462 ↗ |
| Route | Intravenous | “SC or IV injection.” NCT06585462 ↗ |
| Route | Subcutaneous | “SC or IV injection.” NCT06585462 ↗ |